“…Higher response rates have been reported in other HDAC inhibitor studies. A recent trial of abexinostat in 37 patients with FL showed a response rate of 70% [ 19 ]. Differences may be due to patient population or the therapy itself; abexinostat is a pan-HDAC inhibitor, which may have different anti-lymphoma activity compared to the HDAC1-selective activity of mocetinostat.…”